About: Rethinking antiviral effects for COVID-19 in clinical studies: early initiation is key to successful treatment

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Rethinking antiviral effects for COVID-19 in clinical studies: early initiation is key to successful treatment Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Rethinking antiviral effects for COVID-19 in clinical studies: early initiation is key to successful treatment
Creator	Ejima, Keisuke Aihara, Kazuyuki Wakita, Takaji Nakaoka, Shinji Watashi, Koichi Shibuya, Kenji Miyazaki, Taiga Asai, Yusuke Iwami, Shingo Iwanami, Shoya Kim, Koizumi, Yoshiki Perelson, Alan Kohno, Shigeru Fujita, Yasuhisa Fujiu, Katsuhito Kwang, Su Miyazaki, Yoshitsugu Morimoto, Shimpei Noshita, Koji Thompson, N
Source	MedRxiv
abstract	Development of an effective antiviral drug for COVID-19 is a global health priority. Although several candidate drugs have been identified through in vitro and in vivo models, consistent and compelling evidence for effective drugs from clinical studies is limited. The lack of evidence could be in part due to heterogeneity of virus dynamics among patients and late initiation of treatment. We first quantified the heterogeneity of viral dynamics which could be a confounder in compassionate use programs. Second, we demonstrated that an antiviral drug is unlikely to be effective if initiated after a short period following symptom onset. For accurate evaluation of the efficacy of an antiviral drug for COVID-19, antiviral treatment should be initiated before or soon after symptom onset in randomized clinical trials.
has issue date	2020-06-03(xsd:dateTime)
bibo:doi	10.1101/2020.05.30.20118067
has license	medrxiv
sha1sum (hex)	e91724cabbe393c7f7845cd2c3c1fe7931432b37
schema:url	https://doi.org/10.1101/2020.05.30.20118067
resource representing a document's title	Rethinking antiviral effects for COVID-19 in clinical studies: early initiation is key to successful treatment
resource representing a document's body	covid:e91724cabbe393c7f7845cd2c3c1fe7931432b37#body_text
is schema:about of	named entity 'antiviral drug' named entity 'efficacy' named entity 'heterogeneity' named entity 'effective' named entity 'evidence' named entity 'SHORT PERIOD' named entity 'COVID-19' named entity 'evaluate' named entity 'effective' named entity 'vivo' named entity 'antiviral drug' named entity 'evidence' named entity 'heterogeneity' named entity 'antiviral effect' named entity 'viral dynamics' named entity 'antiviral drug' named entity 'COVID-19' named entity 'patients' named entity 'viral load' named entity 'COVID-19' named entity 'randomized clinical trials' named entity 'antiviral effect' named entity 'medRxiv' named entity 'exclusion criteria' named entity 'medRxiv' named entity 'immunomodulation' named entity 'clinical outcomes' named entity 'Singapore' named entity 'Compassionate use programs' named entity 'area under the curve' named entity 'compassionate use programs' named entity 'confounders' named entity 'viral load' named entity 'expected outcome' named entity 'hierarchical clustering' named entity 'peer review' named entity 'parameter estimation' named entity 'COVID-19' named entity 'virus replication' named entity 'rate constant' named entity 'individual variation' named entity 'sample size' named entity 'symptom' named entity 'peer review' named entity 'virus replication' named entity 'peer review' named entity 'antiviral effect' named entity 'preprint' named entity 'sample size' named entity 'peer review' named entity 'SciPy' named entity 'viral dynamics' named entity 'virus' named entity 'preprint' named entity 'virus replication' named entity 'viral load' named entity 'viral load' named entity 'virus infection' named entity 'virus' named entity 'preprint' named entity 'Pairwise comparison' named entity 'viral dynamics' named entity 'virus' named entity 'preprint' named entity 'confounding variables'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software